Transition Therapeutics (TTHI) 8.08 $TTHI Transition

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 7:51 PM

Transition Therapeutics (TTHI) 8.08 $TTHI

Transition Therapeutics Up 43.1% Since SmarTrend Uptrend Call (TTHI)
Comtex SmarTrend(R) - Tue Apr 21, 9:49AM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 11 months, Transition Therapeutics has returned 43.09% as of today's recent price of $7.92.
TTHI: 8.08 (+0.08)

BUYINS.NET: SMCI, PPO, TTHI, HCKT, NEPT, HST Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Apr 15, 6:24AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Super Micro Computer Inc (NASDAQ:SMCI), Polypore International Inc (NYSE

PO), TRANSITION THERAPEUTICS INC (NASDAQ:TTHI), HACKETT GROUP INCORPORATION.(THE) (NASDAQ:HCKT), Neptun SA (NASDAQ:NEPT), Host Hotels and Resorts Inc (NYSE:HST) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
HST: 20.62 (+0.07), SMCI: 31.90 (-2.91), PPO: 58.63 (+0.12), TTHI: 8.08 (+0.08), NEPT: 1.77 (-0.01), HCKT: 9.96 (+0.02)

Transition Therapeutics Has Returned 27.4% Since SmarTrend Recommendation (TTHI)
Comtex SmarTrend(R) - Tue Apr 14, 9:23AM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 10 months, Transition Therapeutics has returned 27.37% as of today's recent price of $7.05.
TTHI: 8.08 (+0.08)

Shares of TTHI Up 23.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 06, 5:26PM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 10 months, Transition Therapeutics has returned 23.39% as of today's recent price of $6.83.
TTHI: 8.08 (+0.08)

Transition Therapeutics Announces Results from Phase 1 AME & Renal Clearance Clinical Studies of Neuropsychiatric Drug Candidate ELND005
PR Newswire - Thu Mar 26, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"

(NASDAQ: TTHI, TSX:TTH) today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME"

study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration ("FDA"

for the approval of most drugs in development.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)

Uptrend Call Working As Transition Therapeutics Stock Rises 27.2% (TTHI)
Comtex SmarTrend(R) - Fri Mar 20, 5:00PM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 9 months, Transition Therapeutics has returned 27.19% as of today's recent price of $7.04.
TTHI: 8.08 (+0.08)

Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in Agitation and Aggression in Patients with Alzheimer's Disease
PR Newswire - Mon Mar 02, 5:02AM CST
Transition Therapeutics Inc. ("Transition" or the "Company"

(NASDAQ: TTHI, TSX: TTH) announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited ("TTIL"

completed enrolment of the Phase 2 clinical study evaluating neuropsychiatric drug candidate ELND005 as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer's disease ("AD"

.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)

Transition Therapeutics concludes public offering of common stock
M2 - Thu Feb 19, 4:04AM CST
Biopharmaceutical company Transition Therapeutics (NASDAQ:TTHI)(TSX:TTH) disclosed on Wednesday the completion of its public offering of 3,538,461 common shares at USD6.50 per share.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)

Transition Therapeutics Inc. Announces Closing of Public Offering of US$23 Million of Common Shares
PR Newswire - Wed Feb 18, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"

(NASDAQ: TTHI, TSX: TTH) today announced the closing of its underwritten public offering of an aggregate of 3,538,461 common shares at a price to the public of US$6.50 per share, including 461,538 common shares issued upon the exercise of the underwriters' over-allotment option. Cowen and Company, LLC was the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC were the co-managers for the offering.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)

22.3% Return Seen to Date on SmarTrend Transition Therapeutics Call (TTHI)
Comtex SmarTrend(R) - Thu Feb 12, 11:04AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 8 months, Transition Therapeutics has returned 22.31% as of today's recent price of $6.77.
TTHI: 8.08 (+0.08)

Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares
PR Newswire - Thu Feb 12, 7:00AM CST
Transition Therapeutics Inc. ("Transition" or the "Company"

(NASDAQ: TTHI, TSX: TTH) today announced the pricing of its underwritten public offering of 3,076,923 common shares at a price to the public of US$6.50 per share for total gross proceeds of US$20 million. The Company has granted the underwriters a 30-day option to purchase up to an additional 461,538 common shares, which could result in an additional US$3 million of gross proceeds. The offering is expected to close on February 18, 2015, subject to customary closing conditions. Cowen and Company, LLC is the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC are the co-managers for the offering.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)

Transition Therapeutics initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:20PM CST

TTHI: 8.08 (+0.08)

Transition Therapeutics Inc. Announces Public Offering of Common Shares
PR Newswire - Wed Feb 11, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"

(NASDAQ: TTHI, TSX: TTH) announced today that it has commenced an underwritten public offering of its common shares. The Company expects to use net proceeds from the sale of the common shares for general corporate purposes, including expenditures related to the advancement of the Company's drug candidates through the various clinical trial phases.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

U.S. Green Beret's Mission: Clearing Landmines in Ukraine

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

OneOdio Showcases Innovation at IFA 2026 in Berlin

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

USPS Honors 150 Years of the U.S. Coast Guard Academy

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Protecting Teeth: Insights from Endodontist Dr. Joubert

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...